Refractory Nephrotic Syndrome Treated with Off-Label Obinutuzumab (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #TH-PO0537; Pres time: Oct 22, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "He was subsequently treated with rituximab, but was later hospitalized due to refractory anasarca requiring IV diuretics. These cases suggest a potential role for earlier use of obinutuzumab in older patients and those with treatment-resistant disease who often develop worse outcomes. Larger studies are needed to better define its efficacy, safety, and long-term outcomes in refractory NS."
Focal Segmental Glomerulosclerosis • Glomerulonephritis • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease
|
|
Mirtha Camila Almanzar; Priscilla Koirala; Mariela Navarro Torres
|